Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMPEL: chemotherapy plus osimertinib versus chemotherapy plus placebo after first-line osimertinib progression
CTR20220911Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2022
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of osimertinib, pemetrexed, cisplatin, carboplatin in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Oct 2022; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20220911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220911.